|
||||||||
 |
|
||||||||
|
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-
of-Action at AACR Annual Meeting
read
more 
TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma
read
more
TransMolecular
Reports Positive Phase 2 Data from Study of 
Iodine
Radiolabeled TM-601 in Recurrent Glioma
read
more
TransMolecular Reports Positive Phase 1 Trial
of
Iodine Radiolabeled
TM-601 in Glioma
read
more
TransMolecular, Inc. Announces Formation of Medical
Advisory Board
read
more
company overview | management | board of directors | investors | medical advisory board | product pipeline | publications & abstracts | completed glioma clinical trials | ongoing clinical trials | future directions | currently recruiting | media relations | press releases | abstracts & articles | in the news | events | research & development | additional resources | advancing targeted cancer therapy | clinical trials | disease information | news | about glioma | glioma | other primary brain tumors | metastatic brain tumors | contact us | careers | site map
Welcome to Transmolecular.com
TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies for glioma, metastatic brain tumors, and aggressive cancers with limited treatment options.
Our experienced team is dedicated to expediting the research and approval processes necessary to bring promising new treatment options – as well as renewed hope – to millions of patients who need them.
In the pages of this website, you will find information about:
| • | High-grade glioma and other cancers that are the focus of our current research |
| • | Our management and clinical research teams |
| • | TransMolecular, Inc.’s proprietary products and technology |
| • | Progress-to-date on our glioma clinical trial program and other clinical trial programs |
| • | Our plans for future development |
